Vedanta Biosciences, an affiliate of PureTech Health developing a new category of therapies for immune-mediated and infectious diseases based on rationally defined consortium of human microbiome-derived bacteria, announced that the United States Patent and Trademark Office (USPTO) has issued four new patents, US 9,801,933, US 9,808,519, US 9,827,276, and US 9,833,483. The new patents broadly cover pharmaceutical compositions including Clostridium bacterial strains and methods of use for therapeutic products, including consortia of bacterial strains and spore-forming fractions based on beneficial bacteria. The newly issued patents are exclusively licensed to Vedanta under an agreement with the University of Tokyo and provide coverage through at least 2031. These issuances further strengthen Vedanta’s leading intellectual property position in the microbiome field, which includes previous issuances US 9,415,079, US 9,421,230, US 9,433,652, US 9,642,882, US 9,662,381, EP2575835, JP5592958, JP5853063, and JP6115971.
“The expansion of our intellectual property estate further establishes Vedanta’s leading IP position in the microbiome field and provides further recognition of the ground-breaking work of Vedanta Biosciences co-founder Dr. Kenya Honda,” said Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences. “We believe The University of Tokyo patents provide Vedanta a significant competitive advantage in the microbiome field in the development of drugs based on bacterial consortia.”
The new U.S. patent issuances broaden the coverage for several programs in Vedanta’s clinical-stage pipeline, including the lead investigational product candidate, VE303, which has just entered the clinic for the treatment of recurrent C. difficile infections. The issuances also provide an additional layer of support for Vedanta’s therapeutic candidates for the treatment of Inflammatory Bowel Disease (IBD), Food Allergy, and other autoimmune and infectious diseases.
